Status:
UNKNOWN
Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease
Lead Sponsor:
Huntington Medical Research Institutes
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Non-Alcoholic Fatty Liver Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Lovaza is the only fish oil supplement approved by the FDA. It is available by prescription for the treatment of hypertriglyceridemia (\> 500 mg/dl). The primary mechanism appears to be a reduction in...
Eligibility Criteria
Inclusion
- Over the age of 18
- Abnormal liver enzymes \>40 IU/L. Definition of normal is ALT 19 for a woman and 30 for a man.
- Patients must meet ATP III criteria for metabolic syndrome: Central obesity as measured by waist circumference. Men - greater than or equal to 40 inches. Women - greater than or equal to 35 inches.
- Blood HDL cholesterol. Men - less than 40 mg/dL. Women - less than 50 mg /dL.
- Blood pressure greater than or equal to 130/85.
- Fasting glucose greater than or equal to 100 mg/dL but less than 126mg/dL on 2 separate occasions.
- Fasting blood triglycerides greater than or equal to 150 mg/dL.
- Hepatitis B and C negative
- Autoimmune Hepatitis, Wilson's Disease, Hemochromatosis negative, etc.
- NASH or NAFLD on biopsy of any degree:
Exclusion
- Below the age of 18.
- Other Causes of Liver inflammation.
- Daily alcohol consumption in excess of 20 grams / day for men and 10 grams / day for women. If participant unable to quantify his/her alcohol intake, they should be excluded.
- Taking a prescribed medication know to cause fatty liver disease 6 months prior to enrollment. Also, subjects with secondary causes of fatty liver disease (ie. Gastric bypass) should be excluded from the study.
- Cirrhosis.
- Subjects on oral insulin-sensitizing agents and other drugs currently being used in the treatment of NAFLD. Such agents include fibrates, Vitamin E, S-adenosyl-methionine, betaine, N-acetylcysteine, and milk thistle extracts.
- Diabetes (fasting sugar above 126mg/dl).
- Pregnancy or lactation. Women of child bearing potential must have a negative serum pregnancy test at screening, a negative urine pregnancy test prior to treatment and be practicing an acceptable form of barrier contraception for the duration of the study.
- Any serious or chronic disease that in the opinion of the Principal Investigator (PI), may affect the assessment of safety or efficacy parameters. This includes but is not limited to, patients with malignancy, other than Basal Cell Carcinomas.
- Patients who, in the opinion of the site PI, are not suitable candidates for enrollment or would not comply with the requirements of the study.
- Patients who have had a liver transplant.
- Any allergy to fish.
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2012
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00941642
Start Date
September 1 2009
End Date
September 1 2012
Last Update
June 10 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
HMRI - Liver Center
Pasadena, California, United States, 91105